Gilead Sciences reported Phase 2 results showing its oral inflammatory bowel disease candidate emvistegrast (2 00 mg daily) eliminated symptoms for patients with moderate-to-severe ulcerative colitis and achieved a 23% placebo-adjusted clinical remission rate at 12 weeks. The company said the result beat Wall Street expectations. Emvistegrast is an oral treatment positioned to expand Gilead’s inflammatory disease pipeline, with the mid-stage readout giving the program a clearer clinical benchmark for further development. Gilead also characterized the data as supportive of a potential best-in-class oral option. The report underscores how oral small-molecule positioning continues to be a key differentiator in UC competitive development, especially when remission endpoints are met at placebo-adjusted levels.